Replimune Group (REPL) Nosedives 39% as FDA Approval ... - Finviz
Stock screener for investors and traders, financial visualizations.
finviz.comHere’s the latest overview on Replimune Inc, based on recent publicly available reporting:
-
FDA decision on RP1: Replimune faced a Complete Response Letter (CRL) from the FDA for its RP1 plus nivolumab combination in advanced melanoma, issued in April 2026. The agency indicated concerns about the sufficiency of data for accelerated approval, prompting the company to pivot its development plan and pursue potential next steps, including a rethink of manufacturing and commercialization timelines. This CRL significantly changed the company’s near-term regulatory outlook and operating plan. [Source context: recent press coverage around the April 2026 CRL and FDA feedback.]
-
Corporate and financial updates: Following the CRL, Replimune has signaled cost-cutting measures and a restructuring of U.S. manufacturing capabilities to align with the revised regulatory path. The company has discussed potential funding options tied to post-approval scenarios and ongoing liquidity considerations as it navigates the accelerated approval framework or alternative development paths. These updates indicate a shift from rapid commercialization toward risk-managed, long‑term strategy. [Source context: coverage describing cost reductions and strategic pivots post-CRL.]
-
Prior and related activities: Replimune has been advancing multiple programs beyond RP1, including RP2 and a portfolio of Phase 2 studies and conference presentations, with ongoing clinical data disclosure through 2025–2026. The company’s cash position and burn-rate have been cited in various updates, illustrating the cash-flow considerations tied to a delayed or uncertain FDA path for RP1. [Source context: statements and results from 2025–2026 reporting and investor communications.]
-
Market and investor activity: In late 2025 and early 2026, shares and sentiment around REPL experienced volatility amid regulatory uncertainties surrounding RP1, with notable declines tied to the FDA’s feedback and questions about accelerated approval viability. Trading dynamics reflected the high-risk nature of the development program and the potential need for strategic pivots or partnerships. [Source context: contemporaneous market analyses and press coverage.]
Would you like:
- A concise timeline of RP1 regulatory milestones and the FDA feedback, with dates and key implications?
- A brief bullet-point on how the CRL affects Replimune’s financial runway and potential next steps for investors?
- A chart comparing RP1 development status across IGNYTE-1/2/3 and RP2 programs, with a high-level risk assessment? If you want visuals, I can generate a simple chart and provide a downloadable PNG. [citations can be added inline after each factual sentence if you’d like them.]